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In order to identify potential markers of renal cancer, the plasma membrane protein content of renal cell carcinoma (RCC)-derived
cell lines was annotated using a proteomics process. One unusual protein identified at high levels in A498 and 786-O cells was CD70
(TNFSF7), a type II transmembrane receptor normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role
in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types demonstrated strong CD70
staining in RCC tissues. Metastatic tissues from eight of 11 patients with clear cell RCC were positive for CD70 expression.
Immunocytochemical analysis demonstrated that binding of an anti-CD70 antibody to CD70 endogenously expressed on the surface
of A498 and 786-O cell lines resulted in the rapid internalisation of the antibody–receptor complex. Coincubation of the internalising
anti-CD70 antibody with a saporin-conjugated secondary antibody before addition to A498 cells resulted in 50% cell killing. These
data indicate that CD70 represents a potential target antigen for toxin-conjugated therapeutic antibody treatment of RCC.
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Advanced renal cell carcinoma (RCC) is generally resistant to
chemotherapy treatment (Yagoda, 1995; Motzer, 1999), and
immunotherapy with interferon-alpha and interleukin-2 (IL-2) as
single agents or in combination with the chemotherapeutic agent
5-fluorouracil is currently used as systemic treatment for some
cases. Response rates remain low at around 15%, and the toxicity
of high-dose IL-2 limits its use (Krown, 1987; Muss, 1998;
Kammula, 1998; van Herpen et al, 2000). Targeted therapeutics
are relatively new to the oncology field, most acting via the
inhibition of mitotic signalling kinases. Therapeutic antibodies
have been exploited for their target specificity and low toxicity,
and many have already been approved for clinical use, including
herceptin (trastuzumab) and erbitux (cetuximab), which target the
activities of cell-surface receptors, her2 and EGFR, respectively, in
solid tumours. Antibodies can also be used to specifically deliver
cytotoxic drugs to tumour cells as immunoconjugates that bind
to, and internalise with, highly expressed cell surface antigens.
An example of an antigen found to be overexpressed in RCC is
carbonic anhydrase IX (CA9), which is the target for the
monoclonal antibody (mAb) G250 (Pastorek et al, 1994; Uemura
et al, 1999; Grabmaier et al, 2000; Li et al, 2001; Bui et al, 2003).
Immunoscintigraphy of RCC patients dosed with iodine-131-
labelled G250 demonstrated tumour targeting to metastatic sites
(Divgi et al, 1998; Steffens et al, 1999; Kennett, 2003).
The aim of this study was to identify other cell-surface proteins
specifically associated with RCC that might be suitable targets for
antibody-targeted cytotoxic therapeutics. To compile a list of
candidate RCC cell-surface proteins, we used a previously
described proteomics approach adapted for breast cancer cell
lines (Adam et al, 2003) using plasma membrane preparations
from the A498, SW839 and CAKI-2 RCC-derived cell lines. As
described previously (Adam et al, 2003), potential targets were
analysed further using real-time quantitative RT–PCR and
immunohistochemistry to quantify expression in normal tissues
and clinical RCC samples. We found CD70, a type II transmem-
brane cell-surface protein of the tumour necrosis factor (TNF)
receptor family (Goodwin et al, 1993; Bowman et al, 1994; Hintzen
et al, 1994), to be expressed at high levels in RCC, with expression
retained in metastatic RCC tissues. We also show that CD70 is
rapidly internalised on binding of an anti-CD70 mAb in RCC-
derived cell lines and that this property allows specific killing of
the CD70-expressing cells by incubating the primary antibody with
a saporin-conjugated secondary antibody. These data demonstrate
that CD70 is a selective biomarker for the diagnosis and/or
treatment of RCC using cytotoxic immunotherapy.
MATERIALS AND METHODS
Preparation of membrane fractions and mass spectrometry
Membrane fractions from the A498 and SW839 RCC-derived cell
lines were prepared from 2 10
8 cells as described previously
(Adam et al, 2003). Purified membrane proteins were resolved Received 22 February 2006; revised 8 May 2006; accepted 11 May 2006
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son a 20cm 6% Laemlli one-dimensional gel (BioRad, Hemel
Hempstead, UK) and 0.5mm slices were subjected to trypsinolysis
and prepared for MALDI-TOF mass spectrometry (Voyager STR,
Applied Biosystems, Framingham, MA, USA) as previously
described (Adam et al, 2003). Selected peptide masses for CD70
(MþH)¼1217.6 and 1142.6 were characterised further by MS/MS
using a tandem quadrupole TOF mass spectrometer equipped with
a nanospray ion source (Micromass UK Ltd, Manchester, UK).
Using the SEQUEST search program (Link et al, 1999), ion
fragmentation mass spectra of these peptides were sequenced by g-
and b-ion analysis, and identified by comparison with a FASTA
database of public domain proteins constructed of protein entries
in the non-redundant database held by the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov) and
ExPasy (http://www.expasy.com).
Human tissues and cell lines
A range of normal frozen tissues (brain, breast, kidney, liver,
tonsil, lymph nodes, skin and thyroid) and tumour tissues
were obtained from the Cellular Pathology Department at the
John Radcliffe Hospital, Oxford, UK together with pre-sectioned
primary and metastatic RCC tissue from Ardais Corporation,
Lexington, MA, USA. Frozen sections of 8mm were cut for
each tissue on a cryostat (Leica Microsystems (UK) Ltd, Milton
Keynes, Bucks, UK) and mounted on Snowcoat X-tra glass
slides (Surgipath Europe Ltd, Peterborough, UK). Following air-
drying for 30min at room temperature (RT), each section
was immersed in 100% acetone for 15min, air dried and then
stored at  201C until required. The human RCC-derived cell lines
SW839 (American Type Culture Collection (ATCC): HTB-49),
A498 (ATCC: HTB-44), 786-O (ATCC: CRL-1932) and ACHN
(ATCC: CRL-1611) were cultured at 371C in a humidified
atmosphere of 95% air and 5% CO2 in growth media specified
by the supplier (ATCC, Manassas, VA, USA). A variety of
B-cell malignancy derived cell lines (RAMOS, BL16, BL58,
AS283, MUTU-III, K562, U937) were kindly provided by Professor
Martin JS Dyer, Department of Haematology, University
of Leicester, UK. Human PBMCs were purified from donor blood
(from the National Blood Service, Bristol, UK) by diluting 1:2 in
PBS, layering over a 20ml ficol solution and spinning at
2500r.p.m. for 20min.
Flow cytometry
Harvested cell lines were washed in Dulbecco’s Phosphate buffered
Salt Solution (DPBS) and resuspended at 1 10
7cellsml
 1.
Adherent cells were detached by incubation in 0.5mM EDTA
in PBS. Peripheral blood mononuclear cells (PBMCs) were
prepared by Ficoll density centrifugation. An aliquot (100ml)
of cell line or PBMCs was then added to each well of a 96-well
plate in triplicate. The cells were pelleted by centrifugation and
washed once in ice-cold DPBS. DPBSþ5% BSA, containing
1mgml
 1 of anti-CD70 antibody BU69 (Ancell Corporation,
Bayport, MN, USA), was then added to each well (200ml).
For control wells, anti-CD70 antibody was substituted for IgG1
isotype control (Serotec Ltd, Oxford, UK). The cells were
then incubated on ice for 60min then washed three times in cold
DPBS and resuspended in DPBSþ5%BSA containing 10mgml
 1
of goat anti-mouse Alexa
488 conjugate (Molecular Probes Inc.,
Eugene, OR, USA). Cells were then incubated for a further
60min on ice, followed by three washes in DPBS, where the
final wash contained propidium iodide (10mgml
 1). Acquisition
of data was performed using a FACScalibur flow cytometer
(FL1þFL3) with an MPM modification and all subsequent
data analysis was performed using CellQuest Pro Software
(Becton-Dickinson).
Immunohistochemistry
Tissue sections were first allowed to warm to RT, then immersed
for 10min in 3% hydrogen peroxide in water to quench
endogenous peroxidase activity followed by washing in water
and then tris-buffered saline (TBS) pH 7.6. A monoclonal mouse
anti-human CD70 antibody, HNE.51 (DakoCytomation, Ely, UK),
which has been well characterised for CD70 staining on frozen
tissues, was applied to the tissues (2mgml
 1 in TBS) for 90min
followed by two 5min washes in TBS. Secondary antibody from the
DakoCytomation Envision anti-mouse system (DakoCytomation,
Ely, UK) was applied for 30min followed by two washes in TBS.
Detection was achieved by a 5min incubation in the presence
of 3,30-diaminobenzidine (DABþ) substrate chromogen, which
results in a brown-coloured precipitate at the antigen site. Sections
were counter-stained in Gills II haematoxylin (Surgipath
Ltd, Richmond, IL, USA) and mounted under glass coverslips
using aqueous mounting medium (Faramount, DakoCytomation,
Ely, UK).
Immunocytochemical analysis of antibody internalisation
Cells were seeded at a density of 5 10
4 cells per chamber of an
eight-well chamber slide and incubated as normal (371C, 5% CO2,
supplier-recommended media) for 24h. The cells were cooled to
41C for 20min to minimise membrane turnover and media were
removed and the cells washed carefully in cold DPBS. Then
1mgml
 1 anti-CD70 antibody BU69 (Ancell Corporation, Bayport,
MN, USA) and isotype control antibody were prepared in 200ml
cold serum free DMEM/F12 media, added to their respective
chambers and incubated at 41C for 20min. Cells were washed twice
with DPBS and the 0h samples fixed in 4% paraformaldehyde for
10min. Warmed media were added to the remaining chambers and
the cells incubated at 371C for 2, 4 and 24h before fixation. After
fixation, the cells were washed twice in DPBS, then blocked/
permeabilised for 20min at RT in 0.1% saponin/5% donkey serum
in DPBS. Biotinylated goat anti-mouse IgG diluted 1:200
(10mgml
 1) in 0.1% saponin/5% donkey serum/PBS was then
added for 1h at RT followed by three washes in DPBS. Extravidin-
Cy3 (Sigma-Aldrich, Poole, UK) diluted 1:500 in 0.1% saponin/5%
MPEEGSGCSVRRRPYGCVLRAALVPLVAGLVICLVVCIQ
RFAQAQQQLPLESLGWDVAELQLNHTGPQQDPRLYWQGG
PALGRSFLHGPELDKGQLRIHRDGIYMVHIQVTLAICSS
TTASRHHPTTLAVGICSPASRSISLLRLSFHQGCTIASQ
RLTPLARGDTLCTNLTGTLLPSRNTDETFFGVQWVRP
20 kDa
Tandem peptide Mass (Da)
LYWQGGPALGR      1217.6
SFLHGPELDK          1142.6
A498 membrane
1D PAGE
Annotation
SwissProt ID: P32970 –CD70
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Figure 1 Proteomic discovery of CD70 in the plasma membrane
fraction of A498 and SW839 renal carcinoma-derived cell lines. The plasma
membrane fraction of A498 and SW839 cell lines was resolved by one-
dimensional PAGE. The proteins contained within 0.5mm consecutive
slices of the gel were subjected to trypsinolysis and analysed by MALDI-
TOF mass spectrometry with selected masses characterised further by MS/
MS using a quadrupole TOF mass spectrometer equipped with a nanospray
ion spray. Using the SEQUEST search program, two uninterpreted ion
fragmentation mass spectra representing peptides LYWQGGPALGR and
SFLHGPELDK identified from the tryptic peptides isolated from a gel slice
taken at around 23kDa were searched against a FASTA database of public
domain proteins and were found to match CD70 (SwissProt accession
P32970).
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sdonkey serum/PBS was added for 30min followed by three washes
in PBS. The cells were then mounted in fluorescence enhancing
mounting media (DakoCytomation, Ely, UK) and examined using
a Leica Microsystems fluorescence microscope with  63 oil
immersion objective.
Saporin-mediated cell killing assay
Antibodies conjugated to the ribosome-inactivating toxin Saporin
(Thorpe et al, 1985) were used to evaluate the ability of CD70 to
perform as a therapeutic antibody target. Briefly, A498 cells were
harvested and resuspended at 1 10
5cellsml
 1. An aliquot of cells
(200ml) was added to each well of a 96-well tissue culture plate and
grown to confluence. Cells were washed with PBS and labelled on
ice with anti-CD70 antibody BU69 (Ancell Corporation, Bayport,
MN, USA) or control IgG1 primary (Serotec Ltd, Oxford, UK) at a
range of concentrations. After 30min, labelled cells were washed
three times with cold PBS. Saporin-conjugated goat anti-mouse
antibody, Hum-Zap (Advanced Targeting Systems, San Diego, CA,
USA), or control antibody was then added to each well to a final
concentration of 5mgml
 1. After incubation for 24h, cells and
debris were harvested from the plate using trypsin digestion and
centrifugation. The recovered cell pellet was then resuspended in
1ml PBS containing propidium iodide (0.1mgml
 1 final) and
percent cell death in each sample calculated by propidium iodide
exclusion analysis using a FACScalibur flow cytometer (Becton-
Dickinson, Oxford, UK) equipped with Cellquest Pro software.
Real-time quantitative RT–PCR
Real-time quantitative RT–PCR analysis of gene expression
(Morrison et al, 1998) was carried out on first-strand cDNA
derived from RNA isolated from samples of normal tissues
(Clontech, Palo Alto, CA, USA) and RCC tissues (Ardais
Corporation, Lexington MA, USA; Peterborough Tissue Bank,
Peterborough, UK). All clinical samples were obtained with
informed patient consent and ethical approval. Each PCR reaction
contained 10ng first-strand cDNA (prepared from each mRNA
sample using Superscriptt reverse transcriptase, Life Technolo-
gies, Carlsbad, CA, USA), SYBR green sequence detection reagents
(Applied Biosystems, Foster City, CA, USA) and sense and anti-
sense primers. All primer pairs traverse at least one intron and test
products have been sequenced to confirm specificity before use
in these assays. PCR products from all samples were analysed on
agarose gels and positives shown to contain a single PCR product
of the size predicted from cDNA. No fragments of the size
predicted from genomic DNA were detected in any samples,
demonstrating the complete absence of genomic DNA contamina-
tion. All reactions were run twice and any samples showing a
410% variation in copy number excluded from the analysis. The
CD70 primers used were as follows: F, gctgctttggtcccattggtcg (exon
1); R, gaggtcctgtgtgattcagctg (exon 2/3 junction; 141bp product).
The CA9 primers used were as follows: F, cagtgcctatgagcagttgctg
(exon 6); R, cttagcactcagcatcactgtc (exon 7; 204bp product). The
PCR conditions used for both sets of primers were one cycle at
501C for 2min, one cycle at 951C for 10min, and 40 cycles of 951C
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Figure 2 CD70 protein is expressed at the cell-surface of kidney cancer-
derived cell lines. An anti-CD70 mAb was used in the context of FACS
analysis to determine relative cell-surface protein levels for A498, 786-0,
SW839 and ACHN renal carcinoma cell lines. The immortalised embryonic
kidney line HEK293 was included as a ‘normal’ kidney cell line control. In
addition, as CD70 expression was first described in B/T cells, a panel of cell
lines with this derivation was included. The CD19þ or CD3þ subsets of
PBMCs were also analysed to confirm the previously observed absence of
binding to these cells. Results demonstrated that expression of CD70 was
highest in A498 and 786-0 cells. Immunocytochemical analysis was
subsequently used to support the finding that CD70 antibody binds to
the surface of A498 cells (inset).
Table 1 List of frozen human malignant tissues immunostained with a
monoclonal anti-CD70 antibody
Tumour type No. of cases Positivity
Bladder
Transitional cell carcinoma 2 —
Brain 1—
Breast
Primary invasive ductal carcinoma 11 —
Breast node
Invasive carcinoma 2 —
Colon
Adenocarcinoma 2 —
Kidney
Renal papillary carcinoma 3 —
Clear cell carcinoma 20 16
Oncocytoma 1 —
Sarcomatoid 1 —
Transitional cell carcinoma 1 —
Neuroblastoma 1 —
Chromophobe 1 —
Wilms tumour 3 —
Liver
Hepatoblastoma 1 —
Lymphoma
Follicular 8 —
Lymphoblastic 4 2
Large cell lymphoma 6 4
B-chronic lymphoid leukaemia 2 —
Skin
Melanoma 1 —
Thyroid
Adenocarcinoma 1 —
Lung
Adenocarcinoma 9 1
Squamous carcinoma 8 —
Clear cell carcinoma 1 —
The number of cases tested for each tumour type is shown along with the number
that were CD70 positive (—denotes that none of the tissues tested were CD70
positive).
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sfor 15s, 651C for 1min. Reaction products were assayed on an ABI
Prism 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) and the accumulation of PCR product was
measured in real time as the increase in SYBR green fluorescence.
Data were analysed using the Sequence Detector program v1.6.3
(Applied Biosystems, Foster City, CA, USA). Standard curves
relating initial template copy number to fluorescence and
amplification cycle were generated using the amplified PCR
product as a template, and were used to calculate copy number
in each sample. Data were expressed as copy number per
nanogram cDNA.
RESULTS
Proteomic discovery of CD70 in RCC-derived cell lines
Purified cell membrane protein preparations were isolated from
the A498, SW839 and CAKI-2 RCC-derived cell lines and
individually separated by one-dimensional PAGE. Sequential
0.5mm gel slices containing the proteins were subjected to
trypsinolysis, and the resulting peptide fragments analysed by
MALDI-TOF and MS/MS (Figure 1). Two ion fragmentation mass
spectra from two tryptic peptides of masses 1217.6 and 1142.6Da,
respectively, were identified in gel slices corresponding to a
molecular weight 23kDa from the A498 and SW839 RCC-derived
cell lines (Figure 1). Using the SEQUEST algorithm (Link et al,
1999), interpretations of these spectra were searched against
a FASTA database of public domain proteins and found to
uniquely match two peptide sequences (LYWQGGPALGR and
SFLHGPELDK) that unambiguously identify the CD70 antigen
(Swiss-Prot accession P32970), a type II transmembrane receptor
also known as CD27L or TNF ligand superfamily member 7
(TNFSF7) (Figure 1).
To confirm and determine the relative cell-surface expression
levels of CD70 in RCC-derived cell lines, the anti-CD70 mAb BU69
was used in FACS analysis. This antibody was selected for FACS
and immunocytochemistry as it gave more consistent results in
these analyses. The A498, 786-0, and ACHN RCC cell lines and the
immortalised HEK293 ‘normal’ kidney cell line were included for
FACS analysis, and, as CD70 expression was first described in
Figure 3 Immunohistochemical analysis of CD70 in RCCs. CD70 expression throughout the carcinoma tissues of frozen sections of clear cell RCC
(ccRCC) is shown (panels i–iii) relative to an isotype matched control antibody (panel iv). CD70 expression was not seen in normal kidney tissues (panel v).
Panels i–v all show images at  20 magnification. Panel vi shows a higher power ( 40) image of a CD70-positive ccRCC tissue demonstrating the plasma
membrane expression of CD70 in the carcinoma cells.
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sactivated B and T cells, a panel of cell lines with this derivation was
also included in the analysis as were the CD19þ and CD3þ
subsets of PBMCs. Results demonstrated that expression of CD70
was highest in the A498, then 786-0 RCC-derived cells (Figure 2).
Expression in the ACHN cell line was approximately five-fold
lower than on the A498 cell line. Cell-surface expression was also
detected on the Raji, BL115, AS283, KHM10B and Mutu-III cell
lines that are all derived from B-cell malignancies; however,
expression on these cell lines was 2–3-fold less than the A498 and
786-O cells (Figure 2). There was no detectable CD70 expression
in the T and myeloid cell lines or donor PBMCs analysed.
Immunocytochemical analysis with BU69 antibody demonstrated
strong membrane reactivity in A498 cells (Figure 2). Scatchard
analysis showed that A498, 786-O and ACHN cell lines endo-
genously expressed 342000, 265000 and 33000 receptors per cell,
respectively. FACS and mRNA analyses were also used to
determine whether the RCC cell lines expressing CD70 also
expressed CD27, the costimulatory receptor for CD70. No
detectable CD27 expression could be seen on any of the RCC cell
lines tested (data not shown).
CD70 is expressed in primary and metastatic RCC tissues
Having discovered high levels of cell-surface CD70 expression
on a number of RCC-derived cell lines, we sought to investigate
CD70 expression in clinical RCC tissues. Immunohistochemistry
on frozen tissue sections was used to determine expression
of CD70 on a number of different types of malignant tissues
including 30 kidney cancer donor tissues. The results of
this analysis are shown in Table 1. In total, 90 donor tumour
tissues were examined; however, only RCC tissues showed strong
staining with the anti-CD70 antibody, with 16 out of 30 (53%)
cases showing CD70 immunoreactivity. Of all the other tumour
tissues examined, weak staining was observed in two of four cases
of lymphoblastic lymphoma, four of six cases of large cell
lymphoma and one of nine cases of lung adenocarcinoma (Table 1).
Examples of CD70 immunostaining of RCC tissues but not normal
kidney are shown in Figure 3.
Expression of CD70 was also examined in 11 clear cell RCC
(ccRCC) metastatic patient tissues, two of which had matched
primary ccRCC tumour tissue for comparison. Eight out of eleven
(73%) metastatic tissues showed some CD70 expression, and for
the two patients with matched primary and metastatic tissues the
intensity of CD70 immunostaining of the primary ccRCC and
metastasis was in each case the same. Examples of CD70
immunostaining of metastatic ccRCC tissues are shown in Figure 4,
in which patient matched primary and metastatic ccRCC CD70
immunostaining is shown (Figure 4, i and ii).
CD70 is rapidly internalised on antibody binding to
RCC-derived cell lines
To determine whether CD70 is a suitable target for cytotoxic-
conjugated antibody therapy, we investigated CD70 internalisation
on antibody binding. An anti-CD70 antibody, BU69, which is
suitable for flow cytometric applications, was added to live
A498 and 786-O cells that had been cooled to minimise membrane
turnover. After a 20min incubation at 41C, a proportion of
the cells were fixed to represent a 0h time point, and warmed
serum was added to the remainder of the cells that were
subsequently fixed at 1, 2 and 4h time points. Evidence
of internalisation of the anti-CD70 antibody–receptor complex
was visualised immunocytochemically as described in Materials
and methods (Figure 5). Results showed that for both A498
and 786-O cells at 0h, there was clear plasma membrane
staining only with the anti-CD70 antibody. However, after 1h of
incubation, there was clear internalisation of the antibody–
receptor complex as evidenced by a reduction in the intensity of
plasma membrane staining and appearance of antibody-containing
vesicles within the cells (Figure 5). Internalisation was even more
pronounced at 2h and after 4h the antibody had completely
internalised.
Figure 4 Immunohistochemical analysis demonstrating that CD70 expression is retained in metastatic tissues derived from primary ccRCC donors. CD70
expression in a primary ccRCC tissue (panel i) is shown alongside expression in a section of adrenal gland metastasis from the same donor (panel ii). Panels iii
and iv show CD70 expression in retroperitoneal region metastasis and lung metastasis respectively from two separate donors with primary ccRCC.
Magnification  20.
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complex to internalise with a toxin and kill RCC cell lines
endogenously expressing CD70, we coincubated the anti-CD70
antibody with an anti-mouse secondary antibody that was
conjugated to saporin before addition to the A498 cell line for
24h. This demonstrated that using 10mgml
 1 primary antibody in
the presence of 5mgml
 1 saporin-conjugated secondary antibody,
approximately 45% of the cells were killed by the addition of anti-
CD70 antibody (Figure 6). In contrast, all the appropriate control
incubations showed approximately 5% cell death. A range of other
primary antibody concentrations was used, with significant cell
killing (25%) observed with 0.08mgml
 1, the lowest concentration
of primary antibody tested (Figure 6).
CD70 exhibits a more restricted normal tissue distribution
and higher prevalence of expression in RCC tissues than
CA9
CA9 is a known antigen currently being targeted for RCC
immunotherapy (Divgi et al, 1998; Steffens et al, 1999; Uemura
et al, 1999; Grabmaier et al, 2000; Li et al, 2001; Bui et al, 2003;
Kennett, 2003). To compare expression of CD70 with CA9, we
performed real-time quantitative RT–PCR analysis on multiple
normal tissues and clinical RCC samples (Figure 7). These data
showed that there was no detectable CD70 mRNA in any of the 29
normal tissues examined; in the thymus, reported expression of
CD70 in the medullary epithelium (Hintzen et al, 1994; Tesselaar
et al, 2003) was likely diluted below the limit of detection by the
presence in this tissue of other, non-expressing cell types. In
contrast, there were high levels of CA9 in the stomach and testis,
and to a lesser extent in the small intestine and prostate. In the
clinical RCC samples, the overall level and prevalence of CD70
mRNA was greater than that of CA9 (Figure 7).
DISCUSSION
Identification of antigens expressed specifically and at high levels
on kidney cancer cells is a key step in the development of effective
immunotherapies for this poorly treated disease. In this paper, we
A
B
0h 1h
2h
4h
4h
0h
Figure 5 Immunocytochemical analysis demonstrating rapid CD70 internalisation on anti-CD70 antibody binding. (A) A498 cells showing anti-CD70
antibody binding to the plasma membrane after incubation at 41C for 20min (0h) followed by clear evidence of internalisation of the antibody (endosomal
compartmentalisation) at 1, 2 and 4h after the addition of growth media at 371C. (B) 786-O cells showing anti-CD70 antibody membrane staining of the
cells at 0h and internalisation after 4h incubation.
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sdescribe the identification of CD70 using proteomic analysis of the
plasma membrane fraction of RCC-derived cell lines. CD70 has a
very restricted normal tissue expression but was found to be
expressed on 16 of 30 RCC clinical specimens and expression was
retained in metastatic tissues from ccRCC. In addition, we have
demonstrated that binding of an anti-CD70 antibody to cell lines
endogenously expressing CD70 results in the rapid internalisation
of the antibody–receptor complex, and can mediate cell killing via
a toxic immunoconjugate.
CD70 is a type II transmembrane protein that was originally
identified as a member of the TNF receptor superfamily with an
expression pattern in normal tissues restricted to germinal centre
B cells, stromal cells of the thymic medulla and scattered T cells
(Goodwin et al, 1993; Bowman et al, 1994; Hintzen et al, 1994).
Subsequent studies have described overexpression of CD70 protein
in mantle cell lymphoma samples (Zhu et al, 2002); on chronic
lymphocytic leukaemia B cells (Lens et al, 1995; Ranheim et al,
1995); and in the tumour cells of thymic carcinomas (Hishima
et al, 2000), undifferentiated nasopharyngeal carcinomas
(Agathanggelou et al, 1995), gliomas and meningiomas (Held-
Feindt and Mentlein, 2002). Additionally, CD70 overexpression
was detected in a multidrug-resistant colonic cell line (SW620-
MDR) (Fan et al, 2004), and as an inducible gene in TNF-alpha-
stimulated human bronchial–epithelial cell line BEAS-2B (Wolf
et al, 2002), and irradiated glioma cell lines (Wischhusen et al,
2002). Our study also identified CD70 expression on B-cell
malignancy-derived cell lines using FACS analysis (Figure 2),
and on six out of twenty clinical lymphoma specimens by
immunostaining (Table 1). Anti-CD70 immunostaining on positive
RCC sections was much stronger than that of the lymphomas in
our study, and quantitative RT–PCR results also showed an overall
higher level of CD70 gene transcription in RCC, indicating that the
protein is highly over-expressed.
CD70 is the ligand for CD27; studies of this interaction have
shown that CD70 promotes cell survival and expansion of antigen-
primed CD8þ T cells, formation of memory T cells and
proliferation of B cells (Brown et al, 1995; Hintzen et al, 1995;
Borst et al, 2005). CD70 protein, whether expressed on dendritic
cells (Hintzen et al, 1995), B cells (Rowley and Al-Shamkhani,
2004), tumour cells (Arens et al, 2001), or introduced as soluble
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Figure 6 Targeting CD70 on A498 cells with an anti-CD70 mAb and
Saporin-conjugated secondary antibody results in specific cell kill.
Histograms show the % cell kill following incubation in a range of primary
antibody concentrations. High levels of cell death were observed only
for cells incubated with anti-CD70 and Saporin-conjugated secondary
antibody. Propidium iodide exclusion analysis was used to calculate the
% cell kill. Mab¼anti-CD70, Mzap¼goat anti-mouse Saporin conjugate,
ISC¼IgG1 isotype control, ConZap¼Saporin-conjugated goat IgG,
anti¼goat anti-mouse IgG. Data shown are representative of three
separate experiments.
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Figure 7 Comparison of the mRNA expression levels of CD70 and CA9 in normal and RCC tissues. Real-time quantitative RT–PCR analysis was used to
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sprotein (Kelly et al, 2002), promotes the survival and expansion of
antigen-primed CD8þ T cells in the mouse, through dose-
dependent stimulation of CD27 activity. CD70–CD27 interactions
may also have a role in memory T-cell formation, which is reduced
by CD70 blockade and enhanced by CD70 overexpression or
recombinant protein infusion (Borst et al, 2005). The effect of
CD70 on B cells is less understood, although in vitro studies
suggest that the CD70–CD27 interaction promotes plasma cell
differentiation (Cormary et al, 2004), whereas other experiments
have demonstrated CD70-driven B-cell proliferation and immu-
noglobulin synthesis (Agematsu et al, 1995; Kobata et al, 1995).
Effects in humans may be more significant than in mice owing to
higher and more consistent expression of CD27 in human B cells.
Our studies showed a high-level expression of CD70 on RCC
cells that might be expected to induce a strong immune response
against the tumour. Frequent expression of CD70 on RCC was
recently also reported by Junker et al (2005). Although RCC is
known to be a highly immunogenic tumour, it is also a very
aggressive cancer that is clearly able to escape immune surveil-
lance. Many other factors are involved in the generation of an
immune response and it has already been shown that CD70-driven
CD8þ T-cell expansion is dependent upon priming. The high
expression of CD70 observed in RCC may be owing to a partial T-
cell induction response, or even simply an incidental result of
activation/amplification of a genomic locus.
We also demonstrated that CD70 on RCC cell lines internalises
rapidly on specific antibody binding, and that this internalisation
can be utilised to transport active cytotoxic molecules into cancer
cells. This was corroborated by a recent paper describing an anti-
CD70 immunoconjugate of doxorubicin that displayed antibody-
mediated toxicity against RCC cell lines (Jeffrey et al, 2006).
The development of effective toxin-conjugated immunothera-
pies will require target antigens that exhibit a highly restricted
expression profile in normal tissues, high expression in primary
and metastatic cancer tissues and rapid internalisation of the
antigen–antibody–toxin complex. CD70 is an antigen that fulfils
all of these criteria, in that it is highly overexpressed in a large
proportion of renal carcinomas, whereas normal tissue expression
is low and restricted to a subset of peripheral blood lymphocytes,
and internalises in response to specific antibody binding.
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